Insider Selling: Guardant Health Inc (GH) Chairman Sells 232,460 Shares of Stock

Share on StockTwits

Guardant Health Inc (NASDAQ:GH) Chairman Amirali Talasaz sold 232,460 shares of the stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $65.60, for a total value of $15,249,376.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of NASDAQ:GH opened at $65.50 on Thursday. Guardant Health Inc has a 12-month low of $27.04 and a 12-month high of $106.58. The stock has a market cap of $5.73 billion and a PE ratio of -23.39.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The company had revenue of $32.87 million for the quarter, compared to the consensus estimate of $24.57 million. On average, sell-side analysts anticipate that Guardant Health Inc will post -1.5 EPS for the current fiscal year.

GH has been the topic of a number of recent research reports. Bank of America reaffirmed a “neutral” rating and set a $60.00 price objective (up from $42.00) on shares of Guardant Health in a research note on Thursday, February 28th. JPMorgan Chase & Co. raised their price objective on Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Wednesday, March 13th. Zacks Investment Research cut Guardant Health from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. Finally, Cowen raised their price objective on Guardant Health from $40.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $82.25.

Several hedge funds and other institutional investors have recently bought and sold shares of GH. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Guardant Health in the fourth quarter worth about $26,000. Mascoma Wealth Management LLC bought a new stake in shares of Guardant Health in the first quarter worth about $54,000. Legal & General Group Plc bought a new stake in shares of Guardant Health in the fourth quarter worth about $85,000. Citigroup Inc. bought a new stake in shares of Guardant Health in the fourth quarter worth about $94,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Guardant Health in the fourth quarter worth about $124,000. 69.47% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was first reported by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://macondaily.com/2019/04/25/insider-selling-guardant-health-inc-gh-chairman-sells-232460-shares-of-stock.html.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.